Faisal Khurshid
Stock Analyst at Leerink Partners
(4.24)
# 434
Out of 5,055 analysts
27
Total ratings
61.9%
Success rate
15.55%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics | Downgrades: Market Perform | $4 | $3.60 | +11.11% | 2 | Nov 7, 2025 | |
| GLPG Galapagos NV | Upgrades: Outperform | $29 → $40 | $30.76 | +30.04% | 2 | Oct 21, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Outperform | $20 | $11.15 | +79.37% | 1 | Sep 25, 2025 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $73 | $84.77 | -13.88% | 1 | Sep 12, 2025 | |
| STTK Shattuck Labs | Maintains: Outperform | $4 → $2 | $1.98 | +1.01% | 2 | Aug 14, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $100.69 | +1.30% | 2 | Jul 10, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $3.13 | -68.05% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $24.36 | +84.73% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $12.79 | +25.10% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.65 | +21.21% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $0.68 | +2,252.25% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 | $64.10 | -6.40% | 2 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $81.97 | -2.40% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $3.99 | +275.94% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $7 | $11.35 | -38.33% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $16.02 | +180.90% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.13 | +519.47% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $4.98 | +60.64% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.73 | +584.93% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $5.41 | +103.33% | 1 | Mar 21, 2023 |
AbCellera Biologics
Nov 7, 2025
Downgrades: Market Perform
Price Target: $4
Current: $3.60
Upside: +11.11%
Galapagos NV
Oct 21, 2025
Upgrades: Outperform
Price Target: $29 → $40
Current: $30.76
Upside: +30.04%
Contineum Therapeutics
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $11.15
Upside: +79.37%
Protagonist Therapeutics
Sep 12, 2025
Initiates: Outperform
Price Target: $73
Current: $84.77
Upside: -13.88%
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $1.98
Upside: +1.01%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $100.69
Upside: +1.30%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $3.13
Upside: -68.05%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $24.36
Upside: +84.73%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $12.79
Upside: +25.10%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.65
Upside: +21.21%
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $0.68
Upside: +2,252.25%
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $64.10
Upside: -6.40%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $81.97
Upside: -2.40%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $3.99
Upside: +275.94%
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $11.35
Upside: -38.33%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $16.02
Upside: +180.90%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.13
Upside: +519.47%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $4.98
Upside: +60.64%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.73
Upside: +584.93%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $5.41
Upside: +103.33%